Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Today’s data show that between Dec. 14, 2020 and June 4, a total of 329,021 total adverse events were reported to VAERS, including 5,888 deaths — an increase of 723 deaths over the previous week. There were 28,441 serious injury reports, up 3,082 compared with last week.
This week’s data for 12- to 17-year-olds show:
- 5,367 total adverse events, including 165 rated as serious and four reported deaths among 12 to 17-year-olds. The youngest deaths reported include two 15-year-olds (VAERS I.D. 1187918 and 1242573), a 16-year-old (VAERS I.D. 1225942) and one 17-year-old (VAERS I.D. 1199455).
- 773 reports of anaphylaxis among 12- to17-year-olds with 98% of cases attributed to Pfizer’s vaccine, 1.8% to Moderna and 0.5% (or four cases) to J&J.
- 59 reports of myocarditis and pericarditis (heart inflammation) with 58 attributed to Pfizer’s COVID vaccine.
- 16 reports of blood clotting disorders, all attributed to Pfizer.
This week’s total VAERS data, from Dec. 14, 2020 to June 4, 2021, for all age groups show:
- 20% of deaths were related to cardiac disorders.
- 51% of those who died were male, 45% were female and the remaining death reports did not include gender of the deceased.
- The average age of death was 74.5.
- As of June 4, 2,012 pregnant women reported adverse events related to COVID vaccines, including 666 reports of miscarriage or premature birth.
- Of the 3,211 cases of Bell’s Palsy reported, 53% were reported after Pfizer vaccinations, 42% following vaccination with the Moderna vaccine and 253 cases, or 8%, of Bell’s Palsy cases were reported in conjunction with J&J.
- 310 reports of Guillain-Barré Syndrome with 45% of cases attributed to Pfizer, 41% to Moderna and 21% to J&J.
- 92,929 reports of anaphylaxis with 41% of cases attributed to Pfizer’s vaccine, 50% to Moderna and 9% to J&J.
- 5,907 reports of blood clotting disorders. Of those, 2,482 reports were attributed to Pfizer, 2,017 reports to Moderna and 1,367 reports to J&J.
CDC to hold emergency hearing after identifying 226 cases of heart inflammation in young people
Based on a May 24 report from the CDC’s Advisory Committee on Immunization Practices COVID-19 Vaccine Safety Technical Work Group, the CDC on June 1 added new language to its guidance:
“Data from VAERS [Vaccine Adverse Events Reporting System] show that in the 30-day window following dose 2 mRNA COVID-19 vaccination, there was a higher number of observed than expected myocarditis/pericarditis cases in 16–24-year-olds.”
During a Thursday meeting of advisors to the U.S. Food and Drug Administration, CDC officials presented data showing a total of 475 cases of myocarditis or pericarditis were recorded in patients 30 and younger following mRNA vaccines.
The CDC identified 226 reports that might meet the agency’s “working case definition” of myocarditis. The majority of those affected have recovered, but 41 had ongoing symptoms, 15 are still hospitalized and three are in the intensive care unit.
No comments:
Post a Comment